![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Beijing (AFP) July 26, 2018
China's drug regulator said it has launched a nationwide inspection of vaccine production as authorities step up the response to a fraud case that has re-ignited public fears over the safety of the country's medicines. The State Drug Administration (SDA) said in an announcement issued late Wednesday that it had dispatched inspection teams "to thoroughly investigate the whole process and entire chain of vaccine production of all vaccine producers". The move comes as authorities rush to bolster public confidence in the country's vaccines, which have been hit by repeated questions about safety and reliability over the years. China's latest product-safety scare emerged more than a week ago with news that major pharmaceutical manufacturer Changchun Changsheng Biotechnology had fabricated records and was ordered to cease production of rabies vaccines. The case leapt to the top of the national agenda last weekend as parents and other consumers vented their anger and frustration at manufacturers and the regulators tasked with supervising them. The government said the problematic rabies vaccine did not leave Changsheng's factory and was not put up for sale. But anger and fear over the failures were quickly exacerbated by additional revelations: the company's vaccine for diphtheria, pertussis and tetanus (DPT) had also failed to meet quality standards, with 250,000 doses sold to Shandong province last year. Further damaging public confidence, authorities in the northern province of Hebei announced Monday that nearly 150,000 people had received sub-standard DPT vaccines made by another firm, Wuhan Institute of Biological Products. - 'Vile' actions - The problems have rekindled already deep fears over domestically made medicines and driven worried parents online to swap information on obtaining imported vaccines, with some vowing not to give their children Chinese-made drugs. The depth of public outrage revealed on social media appeared to have caught authorities off-guard, and national leaders have scrambled in recent days to vow a thorough safety clean-up of the pharmaceutical sector. Police in the northeastern city of Changchun announced on Tuesday that 15 people, including the company's chairwoman, had been arrested on "suspicion of criminal offences". President Xi Jinping -- on a trip to Africa -- weighed in earlier this week by calling the vaccine company's actions "vile in nature and shocking", according to state media. In a further demonstration of government concern, China's cabinet -- the State Council -- sent a team to Changsheng's home province of Jilin to investigate the case with a mandate "to resolutely guard the safety bottom line and maintain social security and stability", the official Xinhua news service said Thursday. China is regularly hit by scandals involving sub-par or toxic food, drugs and other products, despite repeated promises by the ruling Communist Party to address the problem.
![]() ![]() Surge for kids' vaccines in Hong Kong after China scandal Hong Kong (AFP) July 24, 2018 Hong Kong clinics said they have seen a surge in demand for children's vaccines Tuesday after a safety scandal rocked mainland China. The crisis stemmed from falsified production data of a rabies inoculation by a major mainland manufacturer. But vaccines against diphtheria, tetanus and whooping cough, given to babies and infants, were also found to be sub-standard, with doses already sold and administered. The mounting scandal has raised questions about the safety of China's entire vaccine i ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |